Grifols (GRFS) Competitors $7.35 +0.08 (+1.10%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GRFS vs. BGNE, SMMT, GMAB, VTRS, ITCI, MRNA, RDY, CTLT, SRPT, and PCVXShould you be buying Grifols stock or one of its competitors? The main competitors of Grifols include BeiGene (BGNE), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Sarepta Therapeutics (SRPT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Grifols vs. BeiGene Summit Therapeutics Genmab A/S Viatris Intra-Cellular Therapies Moderna Dr. Reddy's Laboratories Catalent Sarepta Therapeutics Vaxcyte BeiGene (NASDAQ:BGNE) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership. Which has more risk & volatility, BGNE or GRFS? BeiGene has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Does the MarketBeat Community prefer BGNE or GRFS? BeiGene received 198 more outperform votes than Grifols when rated by MarketBeat users. Likewise, 69.07% of users gave BeiGene an outperform vote while only 56.02% of users gave Grifols an outperform vote. CompanyUnderperformOutperformBeiGeneOutperform Votes54769.07% Underperform Votes24530.93% GrifolsOutperform Votes34956.02% Underperform Votes27443.98% Which has preferable valuation and earnings, BGNE or GRFS? Grifols has higher revenue and earnings than BeiGene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeiGene$3.32B0.00-$881.71M-$8.24N/AGrifols$7.13B0.71$64.20MN/AN/A Does the media refer more to BGNE or GRFS? In the previous week, BeiGene and BeiGene both had 2 articles in the media. Grifols' average media sentiment score of 0.10 beat BeiGene's score of 0.00 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeiGene 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Grifols 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate BGNE or GRFS? BeiGene presently has a consensus target price of $253.69, indicating a potential upside of 0.00%. Given BeiGene's stronger consensus rating and higher probable upside, research analysts plainly believe BeiGene is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeiGene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Grifols 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Do insiders and institutionals have more ownership in BGNE or GRFS? 48.5% of BeiGene shares are held by institutional investors. 7.4% of BeiGene shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is BGNE or GRFS more profitable? Grifols has a net margin of 0.00% compared to BeiGene's net margin of -25.94%. Grifols' return on equity of 0.00% beat BeiGene's return on equity.Company Net Margins Return on Equity Return on Assets BeiGene-25.94% -25.12% -14.95% Grifols N/A N/A N/A SummaryBeiGene beats Grifols on 8 of the 15 factors compared between the two stocks. Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition Export to ExcelMetricGrifolsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.07B$6.55B$5.38B$9.11BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A9.7087.8117.51Price / Sales0.71334.591,285.9980.25Price / Cash9.2122.6336.6032.90Price / Book0.585.064.944.66Net Income$64.20M$154.90M$117.96M$224.69M7 Day Performance3.75%2.31%2.29%3.11%1 Month Performance-2.46%1.25%3.26%5.17%1 Year Performance8.36%4.88%27.03%22.24% Grifols Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols1.824 of 5 stars$7.35+1.1%N/A+7.5%$5.05B$7.13B0.0023,737BGNEBeiGene1.9979 of 5 starsN/A$253.69+∞N/A$18.03B$3.32B-22.429,000Analyst ForecastPositive NewsSMMTSummit Therapeutics3.0818 of 5 stars$19.03+4.6%$33.57+76.4%+427.1%$14.03B$700,000.00-67.96110Analyst ForecastNews CoverageGMABGenmab A/S4.4025 of 5 stars$20.80-2.0%$45.20+117.3%-28.1%$13.76B$2.39B20.192,204Gap UpVTRSViatris2.038 of 5 stars$11.30-0.4%$13.67+20.9%-0.9%$13.49B$15.43B-15.2738,000ITCIIntra-Cellular Therapies3.8386 of 5 stars$126.200.0%$100.31-20.5%+92.8%$13.38B$612.78M-145.06560High Trading VolumeMRNAModerna4.7452 of 5 stars$34.06+0.9%$75.58+121.9%-65.8%$13.11B$6.85B-5.855,600Gap UpRDYDr. Reddy's Laboratories2.3012 of 5 stars$14.91+0.5%$17.00+14.0%+9.8%$12.44B$3.35B23.8227,048News CoverageCTLTCatalent1.3073 of 5 stars$63.48flat$63.40-0.1%N/A$11.52B$4.38B-28.0916,900Analyst ForecastNews CoverageSRPTSarepta Therapeutics4.9636 of 5 stars$118.00+0.8%$178.71+51.5%+2.0%$11.27B$1.24B94.401,314PCVXVaxcyte2.2203 of 5 stars$85.30-2.9%$145.71+70.8%+40.8%$10.63BN/A-18.54160 Related Companies and Tools Related Companies BGNE Alternatives SMMT Alternatives GMAB Alternatives VTRS Alternatives ITCI Alternatives MRNA Alternatives RDY Alternatives CTLT Alternatives SRPT Alternatives PCVX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GRFS) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRFS Stock Alerts